United Therapeutics
UTHR
676 hedge funds and large institutions have $15.6B invested in United Therapeutics in 2024 Q4 according to their latest regulatory filings, with 105 funds opening new positions, 268 increasing their positions, 213 reducing their positions, and 45 closing their positions.
133% more first-time investments, than exits
New positions opened: 105 | Existing positions closed: 45
26% more repeat investments, than reductions
Existing positions increased: 268 | Existing positions reduced: 213
21% more call options, than puts
Call options by funds: $46M | Put options by funds: $37.9M
21% more capital inflows, than outflows
Capital inflows: $1.13B | Capital outflows: $936M
8% more funds holding
Funds holding: 627 → 676 (+49)
1% more ownership
Funds ownership: 98.31% → 99.31% (+1%)
29% less funds holding in top 10
Funds holding in top 10: 17 → 12 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$145M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$69.8M |
| 3 |
AustralianSuper
Melbourne,
Australia
|
+$59.5M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$57.8M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$40.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$260M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$36.4M |
| 3 |
Avoro Capital Advisors
New York
|
-$36.2M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$35.5M |
| 5 |
Eversept Partners
New York
|
-$32.1M |
UTHR Hedge Fund Activity: Q4 2024 in Review
676 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q4 2024, worth a combined $15.6B — down 0.48% from $15.7B a quarter earlier.
Buyers outnumbered sellers: 105 funds opened new UTHR positions and 45 closed out — a net gain of 60 holders — while 268 added to existing stakes and 213 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $145M. The largest seller was Wellington Management Group, cutting an estimated $260M.
- 676 institutional investors held United Therapeutics (UTHR) as of Q4 2024, up from 627 in Q3 2024.
- Funds reported $15.6B of United Therapeutics stock for Q4 2024, down 0.48% quarter-over-quarter.
- 105 funds opened new United Therapeutics positions in Q4 2024 and 45 closed out, a net change of +60 holders.
- The largest United Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $145M added.
- The largest United Therapeutics seller in Q4 2024 was Wellington Management Group, an estimated $260M sold.
Based on aggregated 13F filings for Q4 2024.